1. Home
  2. Covid 19

Covid 19

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Finfeed Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Next Investors Feb 28, 2022

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

Earlier than Expected - DXB Gets First Regulatory Approval in Europe.

Finfeed Feb 01, 2022

Dimerix (ASX:DXB) just delivered significant progress on its Phase III Clinical Trial for FSGS, with the first EU regulatory approval given for DXB’s kidney disease study in Denmark... earlier than expected.

DXB to run a Phase III COVID-19 Study in Australia

Finfeed Oct 15, 2021

Dimerix (ASX:DXB) is moving fast with its Covid-19 trials, and today announced that this COVID-19 Phase III Study will expand to Australia.

DXB announces approval for Phase III COVID-19 trials

Next Investors Sep 27, 2021

On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.

DXB announces approval for Phase III COVID-19 trials in India

Finfeed Sep 24, 2021

The main drug regulator in India has recommended approval for Dimerix Ltd's (ASX:DXB) Phase 3 clinical trials on its COVID-19 treatment for patients with respiratory complications.

Bod Australia outlines strong revenue growth

Finfeed Archived Apr 22, 2021

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Can BDA’s medical cannabis product treat long-COVID symptoms?

Finfeed Archived Mar 18, 2021

Bod Australia Limited (ASX: BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of long-term symptoms of COVID-19.

Australian stock market still the best performing in the world

Finfeed Archived Mar 12, 2021

The Australian market together with South Africa continue to be the best performing stocks markets in the world and have been for over 100 years.
Page 1 of 9 next >

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X